Brian Harrisberg1

Purpose: To evaluate the clinical outcomes in pseudophakic patients with dry Age Related Macular Degeneration (AMD) and Vitelliform Macular Dystrophy following implantation of the new Scharioth Macula Lens (SML) manufactured by Medicontur.

Method: A retrospective analysis was performed on the clinical outcomes in three eyes of three pseudophakic patients that had implantation of the A45SML plano powered IOL with central +10.0D addition. One patient had dry AMD, another patient had AMD and controlled wet AMD with regular anti‐VEGF treatment and the third patient had Vitelliform Macular Dystrophy. This is a single centre, single surgeon, single IOL study. All patients were evaluated prior to receiving the SML implant against a checklist provided by Medicontur to ensure suitability for the procedure. Surgery was performed through a 2.4 mm temporal incision in all cases. The SML was implanted into the Ciliary Sulcus. Subjective refractions, uncorrected visual acuities at distance, best‐corrected distance and near visual acuities, macula OCT and anterior segment OCT were tested preoperatively and postoperatively in the clinic.

Results: Improvement was noted with near visual acuity in the treated eye of each patient when tested at a reading distance of 15 to 18cms. Most improvement was observed 2 months after surgery and postoperative visual training. Distance visual acuity did not change in any of the patients. The macula OCT examinations remained stable after SML implantation.

Conclusion: The SML appears to be a safe option that can provide useful near vision in pseudophakic patients with maculopathies such as AMD and Vitelliform Macular Dystrophy.